Vladimir Juras1, Markus Schreiner2, Didier Laurent3, Štefan Zbýň4, Vladimir Mlynarik5, Pavol Szomolanyi6, Benedikt Hager7, Celeste Scotti8, Jörg Goldhahn9, Rahel Heule10, Oliver Bieri11, Siegfried Trattnig12. 1. High-Field MR Centre, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria; Institute of Measurement Science, Slovak Academy of Sciences, Bratislava, Slovakia. Electronic address: vladimir.juras@meduniwien.ac.at. 2. High-Field MR Centre, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria; Department of Orthopaedics, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. Electronic address: markus.schreiner@meduniwien.ac.at. 3. Novartis Institutes for Biomedical Research, Department of Translational Medicine, CH-4056 Basel, Switzerland. Electronic address: didier.laurent@novartis.com. 4. High-Field MR Centre, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria; Center for Magnetic Resonance Research, Department of Radiology, University of Minnesota, Minneapolis, Minnesota, USA. Electronic address: szbyn@umn.edu. 5. High-Field MR Centre, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria; Karl-Landsteiner Gesselschaft, St. Pölten, Austria. Electronic address: vladimir.mlynarik@meduniwien.ac.at. 6. High-Field MR Centre, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria; Institute of Measurement Science, Slovak Academy of Sciences, Bratislava, Slovakia. Electronic address: pavol.szomolanyi@meduniwien.ac.at. 7. High-Field MR Centre, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria. Electronic address: benedikt.hager@meduniwien.ac.at. 8. Novartis Institutes for Biomedical Research, Department of Translational Medicine, CH-4056 Basel, Switzerland. Electronic address: celeste.scotti@novartis.com. 9. ETH Zurich, Institute of Translational Medicine, Leopold-Ruzicka-Weg 4, CH-8093 Zurich, Switzerland. Electronic address: jgoldhahn@ethz.ch. 10. High Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Tübingen, Germany. Electronic address: Rahel.Heule@tuebingen.mpg.de. 11. Division of Radiological Physics, Department of Radiology, University of Basel Hospital, Basel, Switzerland. Electronic address: oliver.bieri@unibas.ch. 12. High-Field MR Centre, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria; Christian Doppler Laboratory for Clinical Molecular MR Imaging, Vienna, Austria; Austrian Cluster for Tissue Regeneration, Austria. Electronic address: siegfried.trattnig@meduniwien.ac.at.
Abstract
OBJECTIVE: To investigate T2 mapping as a possible marker for low-grade human articular cartilage lesions during a one-year follow-up, possible changes during the follow-up and compare the reliability and sensitivity of these measurements on high-field (3 T) and ultra-high-field (7 T) MRI scanners. DESIGN: Twenty-one patients with femoral, tibial and patellar cartilage defect in the knee joint participated in the study. The MRI protocol consisted of morphological, as well as three-dimensional triple-echo steady-state (3D-TESS) T2 mapping sequences with similar parameters at 3T and 7T. Patients were scanned at five time-points up to 12 months. T2 values were evaluated in the lesion and healthy-appearing regions for superficial and deep cartilage zone. The repeated ANOVA was used to determine differences in T2 values at various time points. RESULTS: A significant decrease in T2 values was observed between baseline and six months in the superficial layer of the lesion in patients at 3 T (decrease from 41.89 ± 9.3 ms to 31.21 ± 7.2 ms, which is a difference of -5.67 ± 2.2 ms (p = 0.031)), and at 12 months in the superficial layer of the lesion in patients at 3 T (decrease from 41.89 ± 9.3 ms to 35.28 ± 4.9 ms, which is a difference of -6.60 ± 4.4 ms (p = 0.044). No significant differences were recorded at 7 T. CONCLUSION: The change in T2 values acquired with 3 T 3D-TESS appears to be reflecting subtle changes of cartilage composition in the course of low-grade lesion development. 7 T T2 mapping does not reflect these changes probably due to completely decayed short T2 component.
OBJECTIVE: To investigate T2 mapping as a possible marker for low-grade human articular cartilage lesions during a one-year follow-up, possible changes during the follow-up and compare the reliability and sensitivity of these measurements on high-field (3 T) and ultra-high-field (7 T) MRI scanners. DESIGN: Twenty-one patients with femoral, tibial and patellar cartilage defect in the knee joint participated in the study. The MRI protocol consisted of morphological, as well as three-dimensional triple-echo steady-state (3D-TESS) T2 mapping sequences with similar parameters at 3T and 7T. Patients were scanned at five time-points up to 12 months. T2 values were evaluated in the lesion and healthy-appearing regions for superficial and deep cartilage zone. The repeated ANOVA was used to determine differences in T2 values at various time points. RESULTS: A significant decrease in T2 values was observed between baseline and six months in the superficial layer of the lesion in patients at 3 T (decrease from 41.89 ± 9.3 ms to 31.21 ± 7.2 ms, which is a difference of -5.67 ± 2.2 ms (p = 0.031)), and at 12 months in the superficial layer of the lesion in patients at 3 T (decrease from 41.89 ± 9.3 ms to 35.28 ± 4.9 ms, which is a difference of -6.60 ± 4.4 ms (p = 0.044). No significant differences were recorded at 7 T. CONCLUSION: The change in T2 values acquired with 3 T 3D-TESS appears to be reflecting subtle changes of cartilage composition in the course of low-grade lesion development. 7 T T2 mapping does not reflect these changes probably due to completely decayed short T2 component.
Authors: H E Smith; T J Mosher; B J Dardzinski; B G Collins; C M Collins; Q X Yang; V J Schmithorst; M B Smith Journal: J Magn Reson Imaging Date: 2001-07 Impact factor: 4.813
Authors: Z A Cohen; D M McCarthy; S D Kwak; P Legrand; F Fogarasi; E J Ciaccio; G A Ateshian Journal: Osteoarthritis Cartilage Date: 1999-01 Impact factor: 6.576
Authors: D Burstein; J Velyvis; K T Scott; K W Stock; Y J Kim; D Jaramillo; R D Boutin; M L Gray Journal: Magn Reson Med Date: 2001-01 Impact factor: 4.668
Authors: M J Nissi; J Töyräs; M S Laasanen; J Rieppo; S Saarakkala; R Lappalainen; J S Jurvelin; M T Nieminen Journal: J Orthop Res Date: 2004-05 Impact factor: 3.494